Agios Pharm

NASDAQ AGIO

Data sourced from

and

Download Data

Agios Pharm Accounts Payable Turnover Ratio for the year ending December 31, 2023: 2.74

Agios Pharm Accounts Payable Turnover Ratio is 2.74 for the year ending December 31, 2023, a 258.55% change year over year. The accounts payable turnover ratio measures the number of times a company pays off its accounts payable during a specific period. It is calculated by dividing the company's revenue by its accounts payable. This ratio indicates how efficiently a company manages its outstanding payments to suppliers and vendors. A higher turnover ratio suggests that the company is paying off its obligations quickly, while a lower ratio may indicate a slower payment process or potential liquidity issues.

Agios Pharm Accounts Payable Turnover Ratio for the year ending December 31, 2022 was 0.76, a 30,749.30% change year over year.
Agios Pharm Accounts Payable Turnover Ratio for the year ending December 31, 2021 was 0.00, a -99.97% change year over year.
Agios Pharm Accounts Payable Turnover Ratio for the year ending December 31, 2020 was 7.57, a 40.56% change year over year.
Agios Pharm Accounts Payable Turnover Ratio for the year ending December 31, 2019 was 5.39, a 2.01% change year over year.

NASDAQ: AGIO

Agios Pharm

CEO	Dr. Bruce D. Car DACVP, Ph.D.
IPO Date	July 24, 2013
Location	United States
Headquarters	88 Sidney Street, Cambridge, MA, United States, 02139-4169
Employees	383
Sector	Healthcare
Industry	Biotechnology

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key trends